|IsoStilbene is an injectable form of pterostilbene available by licensing and prescription only for use under U.S. Patent No.: 9,682,047.
IsoStilbene is currently offered as part of the Pan American Cancer Treatment Centers Immunotherapy Protocols licensed to them by Therapeutic Solutions International, Inc.
IsoStilbene is used to provide booster dosing of pterostilbene to supplement the 10ml daily intake of NanoStilbene patients already receive as part of their overall treatment.
Peer-reviewed publications have demonstrated the efficacy of the pterostilbene molecule at stimulating immunity to cancer, as well as targeting cancer stem cells[1,2]. Unfortunately, classical formulations of pterostilbene do not appear to deliver effective amounts of pterostilbene to cancer cells. For this reason, Therapeutic Solutions International has developed several alternative dosing formulations including the previously disclosed NanoStilbene, and now, IsoStilbene.
1 Huang et al. Modulation of macrophage polarization and lung cancer cell stemness by MUC1 and development of a related small-molecule inhibitor pterostilbene. Oncotarget. 2016 Jun 28;7(26):3936339375. http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path=8101&pubmed-linkout=1
2 Mak et al. Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-B/microRNA 448 circuit. Mol Nutr Food Res. 2013 Jul;57(7):1123-34. https://www.ncbi.nlm.nih.gov/pubmed/23504987